<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="95606">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01697956</url>
  </required_header>
  <id_info>
    <org_study_id>BDP-AR-307</org_study_id>
    <nct_id>NCT01697956</nct_id>
  </id_info>
  <brief_title>Hypothalamic-Pituitary-Adrenal (HPA)-Axis Study in Pediatric Subjects With Perennial Allergic Rhinitis (PAR)</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 6-Week Study Designed to Investigate the Effects of BDP Nasal Aerosol on the Hypothalamic-Pituitary-Adrenal (HPA)-Axis in Pediatric Subjects (6 to 11 Years of Age) With Perennial Allergic Rhinitis (PAR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teva Pharmaceutical Industries</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Pharmaceutical Industries</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effect of 6 weeks of treatment with
      beclomethasone dipropionate (BDP) nasal aerosol versus placebo on HPA-axis function, as
      assessed by 24-hour serum cortisol weighted mean, and to evaluate the safety and
      tolerability of BDP nasal aerosol, in subjects 6 to 11 years of age with perennial allergic
      rhinitis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>24-Hour serum Cortisol weighted mean after 42 days of treatment</measure>
    <time_frame>Baseline to 42 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>The primary endpoint is the 24-hour serum cortisol weighted mean for BDP nasal aerosol and placebo after forty two (42) days of treatment.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">99</enrollment>
  <condition>Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>Beclomethasone dipropionate (BDP) nasal aerosol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Nasal Aerosol</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Beclomethasone dipropionate (BDP) nasal aerosol</intervention_name>
    <description>Dose: BDP 80 mcg/day (40 mcg/spray, 1 spray/nostril, once daily - total 2 sprays/day)</description>
    <arm_group_label>Beclomethasone dipropionate (BDP) nasal aerosol</arm_group_label>
    <other_name>QNASL (TM)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Nasal Aerosol</intervention_name>
    <description>Dose: 1 spray/nostril, once daily - total 2 sprays/day</description>
    <arm_group_label>Placebo Nasal Aerosol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent/(assent - if applicable)

          -  Male or female subjects 6-11 years of age

          -  General good health

          -  A documented history of PAR to a relevant perennial allergen for a minimum of 12
             months

          -  Other criteria apply

        Exclusion Criteria:

          -  Pregnancy, nursing, or plans to become pregnant or donate gametes

          -  Participation in any investigational drug study within the 30 days preceding the
             Screening Visit 1 (SV1)

          -  Previous participation in a BDP nasal aerosol study as a randomized subject

          -  A known hypersensitivity to any corticosteroid or any of the excipients in the study
             medication formulation

          -  History of physical findings of nasal pathology, including nasal polyps or other
             clinically significant respiratory tract malformations

          -  History of a respiratory infection or disorder within the 14 days preceding the
             Screening Visit 1 (SV1)

          -  Use of any prohibited concomitant medications within the prescribed (per protocol)
             withdrawal periods prior to the Screening Visit 1 (SV1)

          -  Other criteria apply

          -  Current smoker or current user of tobacco products at any time during the study;
             history of smoking or use of tobacco products within the past year
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sudeesh K Tantry, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Teva Branded Pharmaceutical Products, R&amp;D Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Teva Investigational Site 10305</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 10304</name>
      <address>
        <city>Stockbridge</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 10300</name>
      <address>
        <city>Plymouth</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 10302</name>
      <address>
        <city>Normal</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 10301</name>
      <address>
        <city>New Braunfels</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 10303</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 8, 2014</lastchanged_date>
  <firstreceived_date>September 28, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pediatric Subjects</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic, Perennial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Beclomethasone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
